CMPX compasstherapeutics.com Full Business Value

Compass Therapeutics Corp (CMPX) - corporate logo

Compass Therapeutics (CMPX) minimizes capital expenditures by outsourcing production and testing to third-party contractors. This market valuation chart captured the figure -35.69. The portfolio includes promising bispecific antibodies for the therapy of biliary tract tumors currently in the trial stage. Monetization is based on payments from global pharma behemoths and the distribution of drugs through healthcare insurance systems.

CMPX (Compass Therapeutics) Total Company Value history from 11/23/2025 to 10/27/2026

Compass Therapeutics - analytical breakdowns and key metrics (CMPX)

- price and consensus price forecast:
Stock Quotes Compass Therapeutics Inc|CMPX - Price Target Chart
- market capitalization data:
Market Valuation Compass Therapeutics|CMPX - Real Price to Acquire Entire Company
- book capitalization data:
Equity per Share Compass Therapeutics|CMPX - Company Book Value|Market-to-Book Ratio compasstherapeutics.com|CMPX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Compass Therapeutics|CMPX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio compasstherapeutics.com|CMPX - Company Debts|Debts to Book Value Compass Therapeutics
Fundamental valuation:Compass Therapeutics Inc (CMPX)
Original product of Compass Therapeutics, Inc.

Enterprise Value (EV) determines the total acquisition cost of a business by combining market capitalization with net debt. This metric adjusts the stock market valuation for the volume of borrowed funds and available cash to reveal the actual value of the assets. By analyzing Enterprise Value trends, an investor can see the issuer's actual financial weight. For Compass Therapeutics (CMPX), this indicator reflects the value of intellectual capital and patents. Amid FDA clinical trials, EV demonstrates the company's ability to fund development without a critical debt burden.

Competitors of Compass Therapeutics (CMPX)

ImmunityBio Inc - Real Price to Acquire Entire Company|Total Company Value Immunocore PLC|Janux Corp (JANX) - Full Business Value|Real Price to Acquire Entire Company Arcus Biosciences, Inc.|ZYME (zymeworks.com) - Business Value|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Immatics Corp IMTX|Business Value Xencor Inc. (XNCR)|Replimune Group, Inc. - Enterprise Value|lyell.com - Real Price to Acquire Entire Company|IPHA (Innate Pharma) - Total Company Value|PYXS: Total Enterprise Value|cgen.com (CGEN) - Total Company Value|IOBT (IO Biotech Inc.) - Total Company Value|Total Company Value STRO (Sutro Biopharma, Inc.)|Total Enterprise Value minktherapeutics.com|HOWL: Enterprise Value|Full Takeover Company Value immixbio.com IMMX|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)